

Interests Register

Prostate cancer: diagnosis and management (update) committee Publication Date: 24/04/2019

Name	Role with NICE	Type of	Description of	Relevant dates			Comments
		interest inte	interest	Interest arose	Interest declared	Interest ceased	
Waqaar Shah	Committee Chair		None declared				
Abi Ademoyero	Committee member Commissioner		None declared				
Pauline Bagnall	Committee member Specialist Nurse	Direct, Financial	Pre conference dinner paid by Coloplast at the BAUN Annual Conference.	25/11/2017	02/2018		Declare and participate
Pauline Bagnall		Direct, Financial (travel and subsistence only)	Led Flexible cystoscopy workshop and chaired conference sessions including presentation on the PROMIS study at BAUN Annual Conference. Travel and conferences fees	25/11/2017	02/2018		Declare and participate




			paid by BAUN. No other fees received		
Pauline Bagnall		Direct, Non- financial professional and personal	Member Prostate Cancer UK True Nth Steering Group (voluntary role)	17/09/2017	Declare and participate
Pauline Bagnall		Indirect, Financial	Trustee of British Association of Urological Nurses (BAUN) which receives payment from pharmaceutical companies to support promotion of BAUN. Prostate Cancer UK also sponsor workshops and study days organized by BAUN (no payments personally received)	17/09/2017	Declare and participate
Gayan (Guy) Chetiyawardana	Committee member Radiotherapist		None declared		
Charles Frost	Committee member		None declared		
	Lay member				



John Graham	Committee member Clinical Oncologist	Direct, Non- financial	Principal/ co- investigator for Stampede trial. Included within the evidence base for reviews on docetaxel and bisphosphonates	2005	02/2018	Declare and participate – non-commercial trial funding
John Graham		Direct, Financial (travel and subsistence only)	Attendance at ASCO Genito-Urinary Cancer Conference, Orlando, Florida. Conference fee, travel and accommodation paid by Bayer Health Care.	16/02/2017	03/2017	Declare and participate
John Graham		Direct, Financial	Private practice in the non-surgical management of prostate cancer (external beam radiotherapy and chemotherapy). Remuneration is fee for service and practice mostly matches NHS practice.	07/1992	02/2018	Declare and participate Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has



						confirmed that the individual can continue to participate fully.
John Graham		Direct, Non financial	Author of paper included in the evidence base for Review Question on the optimal dose and fractionation schedule for people with localised prostate cancer being treated with radical radiotherapy.		02/2018	Partial exclusion – The Chair declared that JG's expertise was critical to the discussion on the evidence for or Review Question 4 but that JG should be excluded for the drafting of recommendations.
Sadaf Haque	Committee member General		None declared			
Peter Jenkins	Committee member Clinical Oncologist	Direct, Financial (travel and subsistence only)	Bayer funded attendance at ASCO meeting May 2016	05/2017	07/2017	Declare and participate
Peter Jenkins		Direct, Financial	Private practice for patients with prostate cancer. Practice closely mirrors NHS		02/2018	Declare and participate



			practice and is fee for service.		Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully.
Howard Kynaston	Committee member Urological Surgeon	Direct, Financial	Private practice in the assessment and non-surgical and surgical management of prostate cancer. This mirrors NHS practice and is fee for service.	02/2018	Declare and participate Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this



				instance NICE has confirmed that the individual can continue to participate fully.
Howard Kynaston	Direct, Non-financial	Active researcher with publications in the area Author of ProtecT trial included in evidence base for RQ2	03/2017	Partial exclusion – The Chair declared that HK's expertise was critical to the discussion on the evidence for or Review Question 2 but that HK should be excluded for the drafting of recommendations.
Howard Kynaston	Indirect, financial	Clinical Trials where is either the Principle Investigator in Cardiff or co-investigator:	03/2017	Declare and participate – non-commercial funding
		STAMPEDE Trial (MRC trial of adjuvant agents in patients with advanced prostate cancer commencing ADT- proposal to link to PATCH Trial)		
		ProtecT Trial (Randomised trial of treatment of screen		




Sanjeev Madaan	Committee member Urological Surgeon	Direct, Financial	detected prostate cancer) Private practice in the assessment and non-surgical and surgical management of prostate cancer. This mirrors NHS practice is fee for service.	02/2018	Declare and participate Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully.
Brian McGlynn	Committee member Specialist Nurse		None declared		
Jon Oxley	Committee member Pathologist	Direct, Financial	Shareholder in Astra Zeneca,	07/2017	Complete exclusion when committee are discussing pharmaceutical



		Glaxosmithkline and Smith and nephew		management (Review Questions 5, 6 and 7)
Jon Oxley	Direct, Financial	Consultancy for Antev Ltd. Providing guidance on histopathological endpoints for a phase 2 study of a GnRH antagonist (teverelix)	07/2017	Complete exclusion when committee are discussing pharmaceutical management (Review Questions 5, 6 and 7)
Jon Oxley	Direct, Non-financial	Author of ProtecT trial included in evidence base for RQ2	10/07/2018	Partial exclusion – The Chair declared that JO's expertise was critical to the discussion on the evidence for or Review Question 2 but that JO should be excluded for the drafting of recommendations.
Jon Oxley	Direct, Non- financial	Advisor to Prostate Cancer UK charity on active surveillance clinical consensus paper scheduled for publication late 2018		Declare and participate




Jonathan Richenberg	Committee member Uroradiologist	Direct, Non- financial professional and personal	Advisor to Prostate Cancer UK charity, including on active surveillance clinical consensus paper scheduled for publication late 2018		02/2017		eclare and articipate
Jonathan Richenberg		Direct, Non- financial professional and personal	Non-paid advisor to the Multipros trial.		02/2017	e. in	otential partial xclusion if study ncluded in evidence ase
Jonathan Richenberg		Direct, Financial	Organiser of Guerbet sponsored 1 day congress 9th December 2017 in London on mpMRI in prostate cancer. Guerbet are a contrast media manufacturer but their agent is in no way particular to mpMRI prostate. The course is for educational purposes and to improve quality in mpMRI of the prostate.	09/12/2017	10/2017	p. Ee p s; G th R re fr o R	declare and articipate vent is generic and ducational – non-romotional for any pecific product. Guerbet will sponsor the event however Druckhenberg will eceive no income for Guerbet, As rganiser, Druckhenberg will eceive some income for ticket sales for the event e.g. non-commercial income.



Jonathan Richenberg		Direct, Financial	Private practice which mirrors NHS practice. Reports prostate mpMRI under duties as a lead in Uroradiology. Remuneration is fee for service.	02/2018	Declare and participate Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully.
Mark Robinson	Committee member Uroradiologist	Direct, Financial	Reports mpMRI prostate privately in addition to routine NHS mpMRI prostate reporting. Remuneration is on a fee for service basis and practice matches NHS practice.	02/2018	Declare and participate Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise



						r ii c	and a view that the potential for gain is minimal, in this nstance NICE has confirmed that the ndividual can continue to participate fully.
Karen Stalbow	Committee member Lay member	Direct, Financial	Head of Policy, Knowledge & Impact at Prostate Cancer UK	09/2014	08/2017		Declare and remain – no financial benefit
Karen Stalbow		Direct, Non- financial professional and personal	Public statement on access to mpMRI published in the national press March 2018	03/2018	04/2018	c N fi	Full exclusion when discussing Multiparametric MRI for the diagnosis of prostate cancer Review Question 1)
Rhiannon Walters-Davies	Co-opted committee member Pharmacist	Direct, Financial (travel and subsistence only)	Travel and conference paid by Pierre Fabre, for British Thoracic Oncology Group conference	01/2017	01/2018		Declare and participate
Rhiannon Walters-Davies		Direct, Financial (travel and subsistence only)	Travel and conference fees paid by Boehringer, for American Society of Clinical Oncology conference	06/2017	01/2018		Declare and participate



Rhiannon Indirect Financia	Participation in educational event, December 2017 sponsored by Astellas Pharma. Honorarium paid to Velindre Cancer Centre	01/2018	Declare and participate
----------------------------	---	---------	-------------------------

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.